Chikungunya Virus Vaccine Shows Promise in Early Clinical Trial

NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,... [Read More]

Source: The Rheumatologist - April 21, 2020 Category: Rheumatology Authors: Will Boggs, MD Tags: Conditions chikungunya CHIKV polyarthritis vaccine Source Type: research